Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
SABS Stock Summary
In the News
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
SIOUX FALLS, S.D., Feb. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced Samuel J. Reich, the Company's Chairman and CEO, will present an overview of the Company at the BIO CEO & Investor Conference on Monday, February 26, 2024 at 3:15 PM EST.
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
SIOUX FALLS, S.D., Feb. 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced Samuel J. Reich, the Company's Chairman and CEO, will present an overview of the Company at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024 at 1:20 PM EST.
Here's Why SAB Biotherapeutics, Inc. (SABS) Is a Great 'Buy the Bottom' Stock Now
SAB Biotherapeutics, Inc. (SABS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention
SAB Biotherapeutics President & Chief Executive Officer Eddie Sullivan, Ph.D. to present novel DiversitAb™ platform pipeline, with emphasis on partnering influenza therapeutic, SAB-176 SAB Biotherapeutics President & Chief Executive Officer Eddie Sullivan, Ph.D. to present novel DiversitAb™ platform pipeline, with emphasis on partnering influenza therapeutic, SAB-176
SAB Biotherapeutics to Present at Sidoti Virtual Investor Conference, May 10-11
SIOUX FALLS, S.D., May 03, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human, multi-epitope binding immunoglobulin IgG1 (polyclonal) antibodies without the need for human donors, is pleased to announce that Eddie Sullivan, PhD, co-founder, President & CEO of SAB Biotherapeutics, will be presenting and hosting one-on-one meetings with investors at the upcoming Sidoti Virtual Investor Conference on May 10 at 11:30am ET. The presentation can be accessed live at: https://sidoti.zoom.us/webinar/register/WN_hky73f7PSt6rJa3TODNaAQ.
Promising Upsides on these Biotech Penny Stocks
For investors willing to do their research and take calculated risks, biotech penny stocks can offer the potential for high returns. These companies have a low market capitalization and are not yet profitable, but they offer the potential for high growth as their products gain regulatory approval and market acceptance.
SAB Biotherapeutics up 80% after FDA grants fast-track status to flu therapeutic
SAB Biotherapeutics (NASDAQ:SABS) announced on Thursday that the US Food and Drug Administration (FDA) has granted Fast Track designation for its investigational therapeutic SAB-176 for Type A and Type B influenza illness in high-risk patients, including those who have anti-viral resistant strains, causing the company's shares to shoot up more than 80%. A Fast Track designation allows drugmakers to expedite the development and review of medicines that target critical illnesses and address unmet medical needs.
SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco
SIOUX FALLS, S.D., Dec. 15, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies without the need for human donors, announced today that SAB Biotherapeutics has been selected to present at the Biotech Showcase 2023 meeting, an investor conference that drives biotech innovation and global collaboration through presentations delivered by innovative biotech companies, face-to-face networking and one-to-one meetings. The conference is taking place Jan. 9-11 in San Francisco, in parallel with the J.P. Morgan 41st Annual Health Care Conference.
SAB (SABS) Abandons COVID-19 Treatment Study, Stock Plummets
Low hospitalization rates force SAB Biotherapeutics (SABS) to discontinue the late-stage study that is evaluating its COVID-19 antibody treatment. Stock down almost 40% post the announcement.
SAB Biotherapeutics (SABS) Posts Data From COVID Treatment Study
Following positive data from phase II study, SAB Biotherapeutics (SABS) starts a phase III study evaluating its COVID antibody treatment.
SABS Financial details
SABS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.08 | 1.27 | 2.23 | 0.55 | |
Net income per share | -0.22 | 0.46 | -0.64 | -0.43 | |
Operating cash flow per share | -0.21 | 0.23 | 0.14 | 0.09 | |
Free cash flow per share | -0.23 | -0.06 | -0.26 | -0.17 | |
Cash per share | 0.15 | 0.29 | 1.21 | 0.35 | |
Book value per share | -0.05 | 0.9 | 1.41 | 0.71 | |
Tangible book value per share | -0.05 | 0.9 | 1.41 | 0.71 | |
Share holders equity per share | -0.05 | 0.9 | 1.41 | 0.71 | |
Interest debt per share | 0.19 | 0.2 | 0.26 | 0.14 | |
Market cap | 4.41B | 4.41B | 2.14B | 256.75M | |
Enterprise value | 4.41B | 4.41B | 2.11B | 247.64M | |
P/E ratio | -468.57 | 219.34 | -122.4 | -13.7 | |
Price to sales ratio | 1.28K | 79.89 | 35.07 | 10.74 | |
POCF ratio | -478.89 | 441.06 | 568.08 | 68.31 | |
PFCF ratio | -449.21 | -1.62K | -297.17 | -35.73 | |
P/B Ratio | -1.91K | 113.12 | 55.39 | 8.27 | |
PTB ratio | -1.91K | 113.12 | 55.39 | 8.27 | |
EV to sales | 1.28K | 79.8 | 34.64 | 10.36 | |
Enterprise value over EBITDA | -536.04 | 208.57 | -180.06 | -9.12 | |
EV to operating cash flow | -479.03 | 440.61 | 561.04 | 65.89 | |
EV to free cash flow | -449.34 | -1.62K | -293.49 | -34.47 | |
Earnings yield | 0 | 0 | -0.01 | -0.07 | |
Free cash flow yield | 0 | 0 | 0 | -0.03 | |
Debt to equity | -3.31 | 0.21 | 0.17 | 0.19 | |
Debt to assets | 0.42 | 0.14 | 0.08 | 0.12 | |
Net debt to EBITDA | -0.16 | -0.21 | 2.26 | 0.34 | |
Current ratio | 2.01 | 3.11 | 1.96 | 1.47 | |
Interest coverage | -20.24 | 43.82 | -45.48 | -95.89 | |
Income quality | 1.03 | 0.5 | -0.22 | -0.22 | |
Dividend Yield | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 1.19 | 0.12 | 0.28 | 0.69 | |
Research and developement to revenue | 2.33 | 0.51 | 0.94 | 1.52 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.07 | -1.27 | -2.91 | -2.91 | |
Capex to revenue | -0.18 | -0.23 | -0.18 | -0.46 | |
Capex to depreciation | -1.88 | -23.23 | -6.62 | -6.62 | |
Stock based compensation to revenue | 0.11 | 0.02 | 0.04 | 0.1 | |
Graham number | 0.51 | 3.06 | 4.5 | 2.63 | |
ROIC | -0.79 | 0.37 | -0.26 | -0.7 | |
Return on tangible assets | -0.52 | 0.36 | -0.22 | -0.37 | |
Graham Net | -0.27 | 0.24 | -0.06 | -0.01 | |
Working capital | 4.67M | 23.39M | 23.74M | 7.1M | |
Tangible asset value | -2.31M | 39.01M | 38.55M | 31.06M | |
Net current asset value | -11.02M | 16.92M | 7.6M | 2.25M | |
Invested capital | -3.31 | 0.21 | 0.17 | 0.19 | |
Average receivables | 0 | 11.69M | 14.29M | 6.78M | |
Average payables | 0 | 4.78M | 5.92M | 4.07M | |
Average inventory | 0 | 0 | 0 | 0 | |
Days sales outstanding | 298.92 | 135.92 | 48.03 | 84.85 | |
Days payables outstanding | 0 | 0 | 984.13 | 407.94 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | |
Receivables turnover | 1.22 | 2.69 | 7.6 | 4.3 | |
Payables turnover | 0 | 0 | 0.37 | 0.89 | |
Inventory turnover | 0 | 0 | 0 | 0 | |
ROE | 4.08 | 0.52 | -0.45 | -0.6 | |
Capex per share | -0.01 | -0.29 | -0.4 | -0.25 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.08 | 0.05 | 0.01 | 0 | 0.02 | |
Net income per share | -0.15 | -0.18 | -0.15 | -0.14 | -0.1 | |
Operating cash flow per share | -0.19 | 0.63 | -0.03 | -0.1 | -0.1 | |
Free cash flow per share | -0.19 | 0.43 | -0.03 | -0.1 | -0.1 | |
Cash per share | 0.19 | 0.35 | 0.26 | 0.15 | 0.05 | |
Book value per share | 0.71 | 0.71 | 0.48 | 0.39 | 0.29 | |
Tangible book value per share | 0.71 | 0.71 | 0.48 | 0.39 | 0.29 | |
Share holders equity per share | 0.71 | 0.71 | 0.48 | 0.39 | 0.29 | |
Interest debt per share | 0.14 | 0.14 | 0.11 | 0.1 | 0.09 | |
Market cap | 301.65M | 256.75M | 221.75M | 418.5M | 330.16M | |
Enterprise value | 299.12M | 247.64M | 214.15M | 415.63M | 332.38M | |
P/E ratio | -11.89 | -8.15 | -7.49 | -15.21 | -16.18 | |
Price to sales ratio | 84.03 | 118.82 | 381.6 | 4.89K | 260.51 | |
POCF ratio | -36.9 | 9.36 | -138.1 | -85.42 | -63.89 | |
PFCF ratio | -36.55 | 13.85 | -136.29 | -85.03 | -62.85 | |
P/B Ratio | 9.85 | 8.27 | 9.09 | 21.23 | 21.64 | |
PTB ratio | 9.85 | 8.27 | 9.09 | 21.23 | 21.64 | |
EV to sales | 83.33 | 114.6 | 368.52 | 4.86K | 262.27 | |
Enterprise value over EBITDA | -43.49 | -31.76 | -33.35 | -74.81 | -78.65 | |
EV to operating cash flow | -36.6 | 9.03 | -133.37 | -84.84 | -64.32 | |
EV to free cash flow | -36.25 | 13.36 | -131.62 | -84.45 | -63.27 | |
Earnings yield | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 | |
Free cash flow yield | -0.03 | 0.07 | -0.01 | -0.01 | -0.02 | |
Debt to equity | 0.19 | 0.19 | 0.22 | 0.25 | 0.3 | |
Debt to assets | 0.11 | 0.12 | 0.13 | 0.14 | 0.16 | |
Net debt to EBITDA | 0.37 | 1.17 | 1.18 | 0.52 | -0.53 | |
Current ratio | 1.3 | 1.47 | 1.1 | 0.82 | 0.34 | |
Interest coverage | -110.54 | -89.62 | -80.12 | -85.99 | -76.37 | |
Income quality | 1.16 | -4.37 | 0.22 | 0.71 | 1.01 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 1.13 | 1.33 | 5.93 | 33.91 | 2.03 | |
Research and developement to revenue | 2.05 | 3.3 | 7.81 | 42.82 | 3.17 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | -0.32 | 0.01 | 0 | 0.02 | |
Capex to revenue | -0.02 | -4.12 | -0.04 | -0.27 | -0.07 | |
Capex to depreciation | -0.09 | 12.44 | -0.02 | -0.03 | -0.09 | |
Stock based compensation to revenue | 0.16 | 0.12 | 1.04 | 7.54 | 0.5 | |
Graham number | 1.54 | 1.7 | 1.26 | 1.1 | 0.8 | |
ROIC | -0.17 | -0.19 | -0.22 | -0.23 | -0.23 | |
Return on tangible assets | -0.12 | -0.15 | -0.17 | -0.19 | -0.18 | |
Graham Net | -0.09 | -0.01 | -0.09 | -0.15 | -0.2 | |
Working capital | 5.08M | 7.1M | 1.37M | -2M | -6.08M | |
Tangible asset value | 30.62M | 31.06M | 24.4M | 19.72M | 15.26M | |
Net current asset value | 298K | 2.25M | -3.24M | -6.72M | -9.95M | |
Invested capital | 0.19 | 0.19 | 0.22 | 0.25 | 0.3 | |
Average receivables | 11.28M | 9.25M | 3.16M | 563.62K | 182.06K | |
Average payables | 5.21M | 4.58M | 2.56M | 1.42M | 1.24M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 324.48 | 231.43 | 118.19 | 383.2 | 0 | |
Days payables outstanding | 542.45 | 358.54 | 140.87 | 141.6 | 98.92 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0.28 | 0.39 | 0.76 | 0.23 | 0 | |
Payables turnover | 0.17 | 0.25 | 0.64 | 0.64 | 0.91 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.21 | -0.25 | -0.3 | -0.35 | -0.33 | |
Capex per share | 0 | -0.2 | 0 | 0 | 0 |
SABS Frequently Asked Questions
What is SAB Biotherapeutics, Inc. stock symbol ?
SAB Biotherapeutics, Inc. is a US stock , located in Sioux falls of Sd and trading under the symbol SABS
Is SAB Biotherapeutics, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $3. The lowest prediction is $3 and the highest is $3
What is SABS stock prediction ?
What is SAB Biotherapeutics, Inc. stock quote today ?
SAB Biotherapeutics, Inc. stock price is $4.6 today.
Is SAB Biotherapeutics, Inc. stock public?
Yes, SAB Biotherapeutics, Inc. is a publicly traded company.